APA (7th ed.) Citation

Peng, T., Weng, Y., Wu, T., Wu, C., Chou, Y., & Hsu, C. (2024). Efficacy and Safety of Sorafenib or Lenvatinib for Advanced Hepatocellular Carcinoma after Failure of First-Line Atezolizumab Plus Bevacizumab: A Systematic Review and Meta-Analysis. Cancers, 16(16), 2813. https://doi.org/10.3390/cancers16162813

Chicago Style (17th ed.) Citation

Peng, Tzu-Rong, Yi-Fang Weng, Ta-Wei Wu, Chao-Chuan Wu, Yi-Chun Chou, and Ching-Sheng Hsu. "Efficacy and Safety of Sorafenib or Lenvatinib for Advanced Hepatocellular Carcinoma After Failure of First-Line Atezolizumab Plus Bevacizumab: A Systematic Review and Meta-Analysis." Cancers 16, no. 16 (2024): 2813. https://doi.org/10.3390/cancers16162813.

MLA (9th ed.) Citation

Peng, Tzu-Rong, et al. "Efficacy and Safety of Sorafenib or Lenvatinib for Advanced Hepatocellular Carcinoma After Failure of First-Line Atezolizumab Plus Bevacizumab: A Systematic Review and Meta-Analysis." Cancers, vol. 16, no. 16, 2024, p. 2813, https://doi.org/10.3390/cancers16162813.